BillionToOne, Inc.
BLLNHealthcareNASDAQDiagnostics & Research · Last scanned Oct 26, 2026
Scan Results
Daily timeframeBillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. Valued at $5.09B, BLLN is a mid-cap name in its sector. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection.
Market Cap
$5.09B
Beta
—
P/E (TTM)
171.06
P/E (Fwd)
72.57
EPS (TTM)
$0.63
EPS (Fwd)
$1.49
ROE
10.7%
ROA
5.2%
Cash
$548.6M
Total Debt
$143.9M
Free CF
$12.0M
52W Change
-1.1%
Annual Financials
Cash vs Debt
Where BLLN stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, BLLN finished 1.36% below its 150-day moving average ($99.47) and 2.68% above its 200-day moving average ($95.56). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BLLN overbought or oversold?
At the October 19, 2026 close, BLLN's RSI(14) was 28.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $548.6M in cash and $143.9M in debt, BLLN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $12.0M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 10.7%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.2% suggests reasonable efficiency in deploying the company's asset base.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. No single metric tells the full story. Reviewing BLLN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.